Phased Innovation Award Program for AIDS Vaccine Research (R21/R33)

The summary for the Phased Innovation Award Program for AIDS Vaccine Research (R21/R33) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.


	Federal Grant Title:	Phased Innovation Award Program for AIDS Vaccine Research (R21/R33)
	CFDA Number:	93.855
	CFDA Description:	Allergy, Immunology and Transplantation Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	PA-09-119
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Mar 06, 2009
	Creation Date:	Mar 06, 2009
	Original Closing Date for Applications:	Jan 07, 2012
	Current Closing Date for Applications:	Jan 07, 2012
	Archive Date:	Feb 07, 2012
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	Information not provided
	Federal Grant Award Ceiling:	$200,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Grant Description: Purpose. This FOA, issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), solicits research grant applications from institutions/organizations that propose prophylactic vaccine research projects that are innovative, novel, may be high risk/high impact, and that exhibit the potential to advance AIDS prophylactic vaccine design or evaluation. All areas of investigation contributing to the development of an efficacious HIV/AIDS vaccine are welcome. Clinical trials will not be supported under this initiative. Mechanism of Support. This FOA will use the NIH Phased Innovation Award (R21/R33) grant mechanism; Phase I = Exploratory R21/Phase II = Developmental R33. Awards will support milestone-driven exploratory/feasibility proof of concept studies (2 year R21 phase), with possible rapid transition to expanded development (2-3 year R33 phase). Initially funded R21 studies will be evaluated over two years for milestone completion, and R21s that have met defined milestones will be considered for the R33 award.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/pa-09-119.html
Grant Announcement Contact: NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]
Similar Government Grants: • Innovation for HIV Vaccine Discovery (R01); • NIAID Clinical Trial Implementation Cooperative Agreement (U01); • Therapeutics for Neurotropic Biodefense Toxins and Pathogens (R21/R33); • Strategies for the Protection of Pregnant Women and Infants Against Infectious Diseases (R01); • Predictive Biodosimetry: Discovery and Development of Biomarkers for Acute and Delayed Radiation Inj...; • Center for HIV/AIDS Vaccine Immunology (CHAVI); • Genomics of Transplantation Cooperative Research Program; • Asthma and Allergic Diseases Cooperative Research Centers; • Radionuclide Decorporation Agents for Radiation/Nuclear Emergencies: Project BioShield (R01); • Asthma and Allergic Diseases Cooperative Research Centers (U19)